Hims & Hers Stock: FDA Warning, Novo Split, Big Gains

Hims & Hers Stock Jumps Despite Regulatory Scrutiny! Find out why investors are bullish on the telehealth company's growth potential despite FDA warnings and the end of a key partnership. We break down the earnings surge, expansion into men's health, and the stock's wild ride, revealing if this is a buying opportunity or a risky bet. Hosted on Acast. See acast.com/privacy for more information.